Hapoalim Securities Initiates Coverage on Nektar Therapeutics (NKTR) with a Buy; Ongoing Programs to Help Drive Share Price
Tweet Send to a Friend
Hapoalim Securities initiates coverage on Nektar Therapeutics (Nasdaq: NKTR) with a Buy rating and 12-month price target of $14.
Hapoalim ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Hapoalim ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
